AKR1B10 and lung adenocarcinoma: Pan-cancer analysis revealed that compared to non-cancerous tissues, AKR1B10 expression was significantly elevated in cholangiocarcinoma (CHOL), hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate cancer (PRAD), and uterine endometrial cancer (UCEC).